Q: Any reason for the 3% drop today? Is this related to the Keytruda results from a competitor.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
-
Bristol-Myers Squibb Company (BMY $46.86)
-
Knight Therapeutics Inc. (GUD $6.13)
-
iShares U.S. Medical Devices ETF (IHI $60.97)
Q: I have an average price on BMY shares of $69 having bought near peak price...when the recommendations by other analysts ( not 5i) were extremely positive. After, the company missed expectations with a drug and the downfall began. Now, I am wondering, what factors would you consider in making the decision whether to exit this losing trade and put the $$ into an alternate pharm company such as GUD or an ETF such as some you have recently mentioned IHI.
Q: Any idea why BMY tanked, down 11% Friday?
Thanks for your ongoing efforts toward your subscribers.
Mark
Thanks for your ongoing efforts toward your subscribers.
Mark
Q: HELLO, CAN YOU PLEASE ADVISE IF IT IS BETTER TO ADD ON TO GILD OR BMY AT THIS TIME. THANKS
Q: Hello 5i team
I was curious if you thought that the move on Bristol Myers was over done and that this may be a opportunity to buy in?
I was curious if you thought that the move on Bristol Myers was over done and that this may be a opportunity to buy in?
-
Walgreens Boots Alliance Inc. (WBA $11.52)
-
Bristol-Myers Squibb Company (BMY $46.86)
-
Pfizer Inc. (PFE $25.65)
Q: Hello Team,
Would you prefer Pfizer or Bristol Myers in this space, or, given the electioneering going on in the U.S. would something like Walgreens be your preference in the Health Care space?
Thank You,
Barry
Would you prefer Pfizer or Bristol Myers in this space, or, given the electioneering going on in the U.S. would something like Walgreens be your preference in the Health Care space?
Thank You,
Barry
Q: Bristol Myers(BMY)has had a very good run in the past 12 months, but revenue growth and earnings growth are going in the wrong direction. The company seems expensive at current levels. Is drug pipeline hope causing the premium and is it warranted or is the company just over-priced?
Thanks!
Thanks!